Literature DB >> 19253983

14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

H Moynihan1, A R Jales, B M Greedy, D Rennison, J H Broadbear, L Purington, J R Traynor, J H Woods, J W Lewis, S M Husbands.   

Abstract

14-O-Cinnamoyl esters of naltrexone (6) were synthesized and evaluated in isolated tissue assays in vitro and in vivo in mouse antinociceptive assays. Their predominant opioid receptor activity was mu receptor (MOR) antagonism, but the unsubstituted cinnamoyl derivative (6a) had partial MOR agonist activity in vitro and in vivo. When compared to the equivalent 14-cinnamoylaminomorphinones (5), the cinnamoyloxy morphinones (6) as MOR antagonists had a shorter duration of action and were less effective as pseudoirreversible antagonists. The antinociceptive activity of the cinnamoyloxycodeinones (7) was not significantly greater than that of the morphinones (6), but they exhibited no evidence of any pseudoirreversible MOR antagonism. In both respects, these profiles differed from those of the equivalent 14-cinnamoylaminocodeinones (4).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253983      PMCID: PMC3063885          DOI: 10.1021/jm8012272

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

Authors:  L Toll; I P Berzetei-Gurske; W E Polgar; S R Brandt; I D Adapa; L Rodriguez; R W Schwartz; D Haggart; A O'Brien; A White; J M Kennedy; K Craymer; L Farrington; J S Auh
Journal:  NIDA Res Monogr       Date:  1998-03

2.  Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.

Authors:  J H Broadbear; T L Sumpter; T F Burke; S M Husbands; J W Lewis; J H Woods; J R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

3.  Very long-acting narcotic antagonists: the 14 beta-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives.

Authors:  M D Aceto; E R Bowman; E L May; L S Harris; J H Woods; C B Smith; F Medzihradsky; A E Jacobson
Journal:  Arzneimittelforschung       Date:  1989-05

4.  Novel enzymatic synthesis of 4-O-cinnamoyl quinic and shikimic acid derivatives.

Authors:  Nuria Armesto; Miguel Ferrero; Susana Fernández; Vicente Gotor
Journal:  J Org Chem       Date:  2003-07-11       Impact factor: 4.354

Review 5.  Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.

Authors:  Stephen M Husbands; John W Lewis
Journal:  Mini Rev Med Chem       Date:  2003-03       Impact factor: 3.862

6.  In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.

Authors:  G Zernig; E R Butelman; J W Lewis; E A Walker; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

7.  14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity.

Authors:  A Sebastian; J M Bidlack; Q Jiang; D Deecher; M Teitler; S D Glick; S Archer
Journal:  J Med Chem       Date:  1993-10-15       Impact factor: 7.446

8.  Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.

Authors:  Elisabeth Greiner; Mariana Spetea; Roland Krassnig; Falko Schüllner; Mario Aceto; Louis S Harris; John R Traynor; James H Woods; Andrew Coop; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2003-04-24       Impact factor: 7.446

9.  Common anionic receptor site hypothesis: its relevance to the antagonist action of naloxone.

Authors:  R J Kobylecki; R W Carling; J A Lord; C F Smith; A C Lane
Journal:  J Med Chem       Date:  1982-02       Impact factor: 7.446

10.  Activities of mixed NOP and mu-opioid receptor ligands.

Authors:  B Spagnolo; G Calo; W E Polgar; F Jiang; C M Olsen; I Berzetei-Gurske; T V Khroyan; S M Husbands; J W Lewis; L Toll; N T Zaveri
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

View more
  6 in total

1.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

2.  14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.

Authors:  Subramaniam Ananthan; Surendra K Saini; Christina M Dersch; Heng Xu; Nicholas McGlinchey; Denise Giuvelis; Edward J Bilsky; Richard B Rothman
Journal:  J Med Chem       Date:  2012-09-27       Impact factor: 7.446

3.  Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols.

Authors:  Malliga R Iyer; Yong Sok Lee; Jeffrey R Deschamps; Richard B Rothman; Christina M Dersch; Arthur E Jacobson; Kenner C Rice
Journal:  Bioorg Med Chem       Date:  2009-11-18       Impact factor: 3.641

4.  Novel 6β-acylaminomorphinans with analgesic activity.

Authors:  András Váradi; Sándor Hosztafi; Valerie Le Rouzic; Gergő Tóth; Ákos Urai; Béla Noszál; Gavril W Pasternak; Steven G Grinnell; Susruta Majumdar
Journal:  Eur J Med Chem       Date:  2013-09-22       Impact factor: 6.514

5.  Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.

Authors:  Humphrey A Moynihan; Ian Derrick; Jillian H Broadbear; Benjamin M Greedy; Mario D Aceto; Louis S Harris; Lauren C S Purington; Mark P Thomas; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2012-10-31       Impact factor: 7.446

6.  Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile.

Authors:  Vinod Kumar; Willma E Polgar; Gerta Cami-Kobeci; Mark P Thomas; Taline V Khroyan; Lawrence Toll; Stephen M Husbands
Journal:  Front Psychiatry       Date:  2018-09-19       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.